GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panaxia Labs Israel Ltd (XTAE:PNAX) » Definitions » Piotroski F-Score

Panaxia Labs Israel (XTAE:PNAX) Piotroski F-Score : 2 (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Panaxia Labs Israel Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panaxia Labs Israel has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Panaxia Labs Israel's Piotroski F-Score or its related term are showing as below:

XTAE:PNAX' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 4
Current: 2

During the past 8 years, the highest Piotroski F-Score of Panaxia Labs Israel was 4. The lowest was 1. And the median was 2.


Panaxia Labs Israel Piotroski F-Score Historical Data

The historical data trend for Panaxia Labs Israel's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panaxia Labs Israel Piotroski F-Score Chart

Panaxia Labs Israel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A 4.00 2.00 1.00 2.00

Panaxia Labs Israel Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 1.00 2.00 2.00

Competitive Comparison of Panaxia Labs Israel's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Panaxia Labs Israel's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panaxia Labs Israel's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panaxia Labs Israel's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Panaxia Labs Israel's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Jun22) TTM:
Net Income was -13.058 + -12.462 + 0 + 0 = ₪-25.52 Mil.
Cash Flow from Operations was -9.697 + -1.115 + 0 + 0 = ₪-10.81 Mil.
Revenue was 10.603 + 5.614 + 0 + 0 = ₪16.22 Mil.
Gross Profit was -4.445 + -10.687 + 0 + 0 = ₪-15.13 Mil.
Average Total Assets from the begining of this year (Jun22)
to the end of this year (Dec23) was
(66.004 + 52.527 + 39.73 + 21.995 + 5.246) / 5 = ₪37.1004 Mil.
Total Assets at the begining of this year (Jun22) was ₪66.00 Mil.
Long-Term Debt & Capital Lease Obligation was ₪20.88 Mil.
Total Current Assets was ₪4.02 Mil.
Total Current Liabilities was ₪19.98 Mil.
Net Income was -6.427 + -10.295 + -9.106 + -8.644 = ₪-34.47 Mil.

Revenue was 22.503 + 23.811 + 13.713 + 9.489 = ₪69.52 Mil.
Gross Profit was 2.174 + -0.211 + -0.397 + -4.193 = ₪-2.63 Mil.
Average Total Assets from the begining of last year (Jun21)
to the end of last year (Jun22) was
(79.322 + 94.18 + 88.697 + 84.002 + 66.004) / 5 = ₪82.441 Mil.
Total Assets at the begining of last year (Jun21) was ₪79.32 Mil.
Long-Term Debt & Capital Lease Obligation was ₪1.75 Mil.
Total Current Assets was ₪53.37 Mil.
Total Current Liabilities was ₪62.01 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panaxia Labs Israel's current Net Income (TTM) was -25.52. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Panaxia Labs Israel's current Cash Flow from Operations (TTM) was -10.81. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun22)
=-25.52/66.004
=-0.38664323

ROA (Last Year)=Net Income/Total Assets (Jun21)
=-34.472/79.322
=-0.43458309

Panaxia Labs Israel's return on assets of this year was -0.38664323. Panaxia Labs Israel's return on assets of last year was -0.43458309. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Panaxia Labs Israel's current Net Income (TTM) was -25.52. Panaxia Labs Israel's current Cash Flow from Operations (TTM) was -10.81. ==> -10.81 > -25.52 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Dec23
=20.881/37.1004
=0.56282412

Gearing (Last Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=1.748/82.441
=0.02120304

Panaxia Labs Israel's gearing of this year was 0.56282412. Panaxia Labs Israel's gearing of last year was 0.02120304. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4.02/19.98
=0.2012012

Current Ratio (Last Year: Jun22)=Total Current Assets/Total Current Liabilities
=53.367/62.009
=0.86063313

Panaxia Labs Israel's current ratio of this year was 0.2012012. Panaxia Labs Israel's current ratio of last year was 0.86063313. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Panaxia Labs Israel's number of shares in issue this year was 0.151. Panaxia Labs Israel's number of shares in issue last year was 0.144. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-15.132/16.217
=-0.9330949

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-2.627/69.516
=-0.03778986

Panaxia Labs Israel's gross margin of this year was -0.9330949. Panaxia Labs Israel's gross margin of last year was -0.03778986. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun22)
=16.217/66.004
=0.24569723

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun21)
=69.516/79.322
=0.8763773

Panaxia Labs Israel's asset turnover of this year was 0.24569723. Panaxia Labs Israel's asset turnover of last year was 0.8763773. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Panaxia Labs Israel has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Panaxia Labs Israel  (XTAE:PNAX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Panaxia Labs Israel Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Panaxia Labs Israel's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Panaxia Labs Israel (XTAE:PNAX) Business Description

Traded in Other Exchanges
N/A
Address
Jabotinsky Street 7, Ramat Gan, ISR, 52520
Panaxia Labs Israel Ltd is engaged in the manufacture and distribution of medical cannabis products. The firm offers a wide range of products comprising oral tablets, sublingual tablets, medical oils, concentrations, pastilles, suppositories, topical creams, pain relief creams, and pain relief patches.

Panaxia Labs Israel (XTAE:PNAX) Headlines

No Headlines